Evidence map›Paper›PMID 37103638›Full record

ArticleCEN case reports2024

A case of rapidly progressive glomerulonephritis with double-positive anti-GBM antibody and MPO-ANCA after SARS-CoV-2 vaccination and relapse during 1 year follow-up.

Kanako Terakawa, Takahito Niikura, Daisuke Katagiri, Akiho Sugita, Tatsuya Kikuchi, Ayaka Hayashi, Minami Suzuki, Hideki Takano

Open access · bronzeAbstract readCase Reports
In one paragraph

Article in CEN case reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Kanako TerakawaDepartment of Nephrology, National Center for Global Health and Medicine, 1-21-1, Toyama, Shinjyuku-Ku, Tokyo, Japan.
Takahito NiikuraDepartment of Nephrology, National Center for Global Health and Medicine, 1-21-1, Toyama, Shinjyuku-Ku, Tokyo, Japan.
Daisuke KatagiriDepartment of Nephrology, National Center for Global Health and Medicine, 1-21-1, Toyama, Shinjyuku-Ku, Tokyo, Japan. dkatagiri@hosp.ncgm.go.jp.ORCID 0000-0003-1395-2644
Akiho SugitaDepartment of Nephrology, National Center for Global Health and Medicine, 1-21-1, Toyama, Shinjyuku-Ku, Tokyo, Japan.
Tatsuya KikuchiDepartment of Nephrology, National Center for Global Health and Medicine, 1-21-1, Toyama, Shinjyuku-Ku, Tokyo, Japan.
Ayaka HayashiDepartment of Nephrology, National Center for Global Health and Medicine, 1-21-1, Toyama, Shinjyuku-Ku, Tokyo, Japan.
Minami SuzukiDepartment of Nephrology, National Center for Global Health and Medicine, 1-21-1, Toyama, Shinjyuku-Ku, Tokyo, Japan.
Hideki TakanoDepartment of Nephrology, National Center for Global Health and Medicine, 1-21-1, Toyama, Shinjyuku-Ku, Tokyo, Japan.
National Center for Global Health and Medicine · JP

Funding

Grants-in-Aid for Research from the National Center for Global Health and Medicine 21A2002
6 · The paper itself

Abstract

Although mRNA vaccines for COVID-19 are highly beneficial and are recommended for patients with kidney disease, adverse reactions in some patients after vaccination have been problematic. Various vasculitis and renal disorders have been reported after vaccination; however, a causal relationship has not yet been identified. In this report, we describe a case of rapidly progressive glomerulonephritis that developed after SARS-CoV-2 vaccination, in which both anti-glomerular basement membrane (anti-GBM) and myeloperoxidase antineutrophil cytoplasmic antibodies (MPO-ANCA) were present. The patient's renal biopsy showed that of the 48 glomeruli in total, four showed global sclerosis and none showed segmental sclerosis. The biopsy showed 11 cellular glomerular crescents and 5 fibrocellular glomerular crescents. Renal function improved with steroids, rituximab, and plasma exchange. Approximately 9 months later, MPO-ANCA was again elevated, and the pulmonary lesions worsened, again requiring multidisciplinary treatment. This case suggests that caution should be exercised in the development of double-positive disease after vaccination, and that long-term observation may be necessary because of the possibility of relapse.

Indexed as

AutoantibodiesCOVID-19GlomerulonephritisNephritisAntibodies, Antineutrophil CytoplasmicChronic DiseaseCOVID-19 VaccinesFollow-Up StudiesGlomerular Basement MembraneHumansPeroxidaseRecurrenceSARS-CoV-2SclerosisVaccinationAntibodies, Antineutrophil Cytoplasmicantiglomerular basement membrane antibodyAutoantibodiesCOVID-19 VaccinesPeroxidaseAnti-GBM diseaseMPO-ANCASARS-CoV-2 vaccination

Identifiers

PMID37103638
PMCPMC10133896
OpenAlexW4367175089

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.